Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Study of the Effectiveness and Safety of Galantamine Hydrobromide on Cognitive Impairment in Patients With Schizophrenia.

This study has been completed.
Information provided by:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Identifier:
First received: February 11, 2004
Last updated: May 20, 2011
Last verified: April 2010
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: February 2005
  Estimated Primary Completion Date: No date given